peoplePerson
Funda Meric-Bernstam
Funda Meric-Bernstam runs the world's largest phase 1 programme and led the tumour-agnostic HER2 ADC study.
Surgical oncologist turned early-drug-development leader. Directs MD Anderson's Institute for Personalized Cancer Therapy and chaired DESTINY-PanTumor02, which led to the tumour-agnostic approval of trastuzumab deruxtecan for HER2 IHC 3+ solid tumours.
Role
Chair, Investigational Cancer Therapeutics, MD Anderson
Institution
Specialisms
Phase 1 trialsPrecision oncologyHER2
| Title | Journal | Year |
|---|---|---|
| Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial | Journal of Clinical Oncology | 2024 |
| Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials | Journal of Clinical Oncology | 2015 |
Pages like this
not linked directly; found by shared links- IdeaHER2 ADCs as standard for HER2-positive serous endometrial cancer
Shares DESTINY-PanTumor02, Trastuzumab deruxtecan, HER2.
- CompanyLabcorp
Shares Companion diagnostics, Comprehensive genomic profiling.
- TrialDESTINY-CRC02
Shares Trastuzumab deruxtecan, HER2.
- PersonBob T. Li
Shares Trastuzumab deruxtecan, HER2.
- ProductTrastuzumab duocarmazine
Shares Trastuzumab deruxtecan, HER2.
- ProductFoundationOne CDx / Liquid CDx
Shares Companion diagnostics, Comprehensive genomic profiling.
- InstitutionInstituto Alexander Fleming
Shares HER2, Comprehensive genomic profiling.
- PersonJeeyun Lee
Shares HER2, Comprehensive genomic profiling.